[PRNewswire] Regulus Therapeutics Inc (NASDAQ:RGLS)(TREND ANALYSIS) announced the appointment of Michael Huang, M.D. as Vice President, Clinical Development. Dr. Huang is an experienced drug developer with proven success in advancing programs through clinical trials that led to commercialization in a wide range of therapeutic areas. At Regulus, Dr. Huang will be responsible for leading the company’s global clinical operations and medical affairs and will serve as a key member of the executive leadership team.
“Over the last two and a half years, Regulus has executed well on our ‘Clinical Map Initiative’ goals and we’ve advanced our lead microRNA therapeutic programs into important stages of clinical development. RG-101 is being tested in Phase II, RG-012 is being tested in Phase I, and RG-125 is expected to enter the clinic by the end of 2015,” said Paul Grint, M.D., President and CEO of Regulus. “To continue to strengthen our clinical capabilities, we are pleased to welcome Mike to Regulus. His expertise in advancing investigational drugs through both early and late-stage development will greatly enhance our ability to bring microRNA therapeutics to patients in need.”
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Regulus Therapeutics Inc (NASDAQ:RGLS) stock is currently trading 67.11% below its 52-week-high, 35.15% above its 52-week-low. The 1-year stock price history is in the range of $6.23 – $25.6. Regulus Therapeutics Inc (RGLS) has a price to book ratio of 3.41. RGLS stock price has underperformed the Nasdaq by 48.3%. The Medical Drugs company is currently valued at $0.44 billion and its share price closed the last trading session at $8.42. The stock has a 50-day moving average of $7.95 and a 200-day moving average of $12.76.
Regulus Therapeutics Inc (RGLS) current short interest stands at 9.03 million shares. It has decreased by 2% from the same period of last month. Around 33% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.74 million shares, the number of days required to cover the short positions stand at 12.2 days.
RGLS reported last quarter earnings on August 04. The Medical Drugs company announced earnings per share of $-0.41 against a consensus Street estimate of $-0.31, missing estimate by $0.1. This corresponds to a decrease of $0.15 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently five analysts that cover Regulus Therapeutics Inc stock. Of those five, five have a Buy rating. On a consensus basis this yields to a Buy rating. The consensus target price stands at $28.
A recent analyst activity consisted of Guggenheim Securities who initiated their coverage on the stock with Buy rating on June 9. On the date of report, the stock closed at $10.31.
FBR Capital initiated their coverage on the stock with Outperform rating on April 21, and fixed their price target at $30. This corresponds to a 256.29% upside from the last closing price. On the date of report, the stock closed at $17.62.
Another research firm was Deutsche Bank who reiterated their Buy stance on April 6. Deutsche Bank decreased price target from $30 to $27. This translates to a 220.67% upside from the last closing price. On the date of report, the stock closed at $16.39.
Regulus Therapeutics Inc. operates within the biopharmaceutical industry. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulas’s research consists of scientists from across the world.